AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
New Fortress Energy
NFE
Cars.com
CARS
4
Halozyme Therapeutics
HALO
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
ONCO Onconetix
- 0.128
- -0.002-1.77%
Close Mar 21 16:00 ET
- 0.128
- 0.000-0.16%
Post 19:58 ET
1.86MMarket Cap0.00P/E (TTM)
0.129High0.116Low2.14MVolume0.126Open0.130Pre Close265.09KTurnover22.41%Turnover Ratio0.00P/E (Static)14.55MShares21.40052wk High0.05P/B1.22MFloat Cap0.11552wk Low--Dividend TTM9.57MShs Float3636.000Historical High--Div YieldTTM9.82%Amplitude0.115Historical Low0.123Avg Price1Lot Size
About Onconetix Company
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.
Company Profile
SymbolONCO
Company NameOnconetix
Listing DateFeb 18, 2022
Founded2018
CEODr. Ralph Schiess
MarketNASDAQ
Employees23
Fiscal Year Ends12-31
Address201 East 5th Street,Suite 1900
CityCincinnati
ProvinceOhio
CountryUnited States of America
Zip Code45202
Phone1-513-620-4101
Websitehttp://www.onconetix.com
Company Executives
- Name
- Position
- Salary
- Dr. Ralph Schiess
- Chief Executive Officer, Proteomedix AG
- --
- Karina M. Fedasz
- Interim Chief Financial Officer
- --
- James Sapirstein
- Executive Chairman of the Board
- 182.12K
- Dr. Thomas Meier, PhD
- Director
- --
- Andrew J. Oakley
- Director
- --
- Dr. Ajit Singh, PhD.
- Director
- --
- Simon Tarsh
- Independent Director
- 112.62K
- Timothy R. Ramdeen
- Independent Director
- 82.67K
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call